These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29173262)

  • 1. Users' guide to the surgical literature: how to assess a noninferiority trial.
    Thoma A; Farrokhyar F; Waltho D; Braga LH; Sprague S; Goldsmith CH
    Can J Surg; 2017 Dec; 60(6):426-432. PubMed ID: 29173262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some issues for the evaluation of noninferiority trials.
    Xie X; Wang M; Ng V; Sikich N
    J Comp Eff Res; 2018 Sep; 7(9):835-843. PubMed ID: 30192159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Users' guide to the surgical literature: how to assess an article using surrogate end points.
    Gallo L; Eskicioglu C; Braga LH; Farrokhyar F; Thoma A
    Can J Surg; 2017 Aug; 60(4):280-287. PubMed ID: 28730989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to Use a Randomized Clinical Trial Addressing a Surgical Procedure: Users' Guide to the Medical Literature.
    Evaniew N; Carrasco-Labra A; Devereaux PJ; Tikkinen KA; Fei Y; Bhandari M; Guyatt G
    JAMA Surg; 2016 Jul; 151(7):657-62. PubMed ID: 27027568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the noninferiority margin and analysing noninferiority: An overview.
    Althunian TA; de Boer A; Groenwold RHH; Klungel OH
    Br J Clin Pharmacol; 2017 Aug; 83(8):1636-1642. PubMed ID: 28252213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals.
    Angeli F; Verdecchia P; Reboldi G
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):229-238. PubMed ID: 31650521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Most noninferiority trials were not designed to preserve active comparator treatment effects.
    Tsui M; Rehal S; Jairath V; Kahan BC
    J Clin Epidemiol; 2019 Jun; 110():82-89. PubMed ID: 30858020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key insights and challeneges in noninferiority trials.
    Hong B; Lee DK
    Korean J Anesthesiol; 2024 Aug; 77(4):423-431. PubMed ID: 39081188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodological aspects of superiority, equivalence, and non-inferiority trials.
    Stefanos R; Graziella D'; Giovanni T
    Intern Emerg Med; 2020 Sep; 15(6):1085-1091. PubMed ID: 32705494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate.
    Althunian TA; de Boer A; Groenwold RHH; Klungel OH
    J Clin Epidemiol; 2018 Dec; 104():15-23. PubMed ID: 30009941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological quality of oncology noninferiority clinical trials.
    Wayant C; Ross A; Vassar M
    Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninferiority Clinical Trials: The Good, the Bad, and the Ugly.
    Lesaffre E
    Semin Liver Dis; 2018 May; 38(2):97-102. PubMed ID: 29871016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pros and Cons of Noninferiority Trials.
    Ofori S; Tornberg SV; Kilpeläinen TP; Tikkinen KAO; Guyatt GH; Witte LPW
    Eur Urol Focus; 2023 Sep; 9(5):711-714. PubMed ID: 37880063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninferiority trials with nonadherence to the assigned randomized treatment.
    Korn EL; Gray RJ; Freidlin B
    Clin Trials; 2019 Dec; 16(6):673-681. PubMed ID: 31409130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of reporting of noninferiority and equivalence randomized trials.
    Le Henanff A; Giraudeau B; Baron G; Ravaud P
    JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
    Aberegg SK; Hersh AM; Samore MH
    J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine.
    Kaul S
    Can J Cardiol; 2021 Sep; 37(9):1378-1393. PubMed ID: 34118378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology.
    Jatoi I; Gail MH
    JAMA Oncol; 2020 Mar; 6(3):420-424. PubMed ID: 31830235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninferiority Trial Design: Opportunities and Challenges.
    Adidharma W; Nguyen SN; Waljee JF
    J Hand Surg Am; 2022 Nov; 47(11):1101-1106. PubMed ID: 36182582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninferiority studies with multiple reference treatments.
    Li-Ching H; Miin-Jye W; Hung CS; Shing KK
    Stat Methods Med Res; 2017 Jun; 26(3):1295-1307. PubMed ID: 25792542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.